Convergence of the Cox-2 and 5-Lipoxygenase Pathways
Convergence of the Cox-2 and 5-Lipoxygenase Pathways
批准号:
8852624
负责人:
Claus Schneider
金额:
$31.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-01-01 至 2017-12-31
关键词:
AccountingAddressAdhesionsAdverse effectsAffectAnabolismAnimal ModelAnti-Inflammatory AgentsAnti-inflammatoryArachidonate 5-LipoxygenaseArachidonic AcidsArterial Fatty StreakAsthmaAtherosclerosisAttenuatedAutacoidsBasophilsBiochemicalBiochemistryBiologicalBiologyCardiovascular systemCell physiologyCellsComplementCoxibsDataDiseaseDoseEdemaEicosanoidsEndothelial CellsEnzymesEventFamilyFundingGenetic Crossing OverGoalsHumanHydroxyeicosatetraenoic AcidsIn VitroInflammationInflammation MediatorsInflammatoryInflammatory ResponseInvestigationLOX geneLeadLesionLeukocytesLeukotrienesLifeLipidsLipoxinsModelingNamesNon-Steroidal Anti-Inflammatory AgentsPTGS2 genePathway interactionsPeritonealPharmaceutical PreparationsPhysiologicalPhysiological ProcessesProcessProstaglandinsPsoriasisReceptor ActivationRegulationResolutionRoleStagingTestingTherapeuticTissuesanalogangiogenesisatherogenesisbiosynthetic productcancer typechemical synthesiscyclooxygenase 1cyclooxygenase 2designeosinophilfightinggastrointestinalhemiketalhydroxy fatty acidin vivoinsightlipid mediatormacrophagemonocytemouse modelneutrophilnovelnovel therapeuticsresearch studytooltranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The families of eicosanoid lipid mediators formed during inflammation and other physiological and pathophysiological processes include the well-established prostaglandins, leukotrienes, lipoxins, and hydroxy- and epoxy-derivatives of arachidonic acid. These short-lived lipid autacoids regulate crucial steps in the onset and resolution as well as immunological processing of an inflammatory event. Prostaglandins and leukotrienes are biosynthesized via separate pathways following the initial oxygenation of arachidonic acid by either cyclooxygenase-2 (COX-2) or 5-lipoxygenase (5-LOX), respectively. Quite unexpectedly, we discovered that the 5-LOX and COX-2 enzymes could be acting in tandem resulting in the biosynthesis of previously unrecognized eicosanoids: Consecutive oxygenation of AA by 5-LOX and COX-2 gives an unstable di- endoperoxide that rearranges to two novel hemiketal eicosanoids that we named hemiketal (HK) D2 and HKE2. In preliminary experiments we have shown biosynthesis of HKD2 and HKE2 in mixtures of activated human leukocytes and their biological activity in stimulating endothelial cell tubulogenesis, two key findings that implicate the hemiketals as novel lipid autacoids in inflammation. In Specific Aim 1 we will test the hypothesis that biosynthesis of the hemiketals is regulated by endogenous w-3 analogs of 5-HETE, and that NSAIDs and COX-2 specific drugs affect hemiketal formation at lower doses than prostaglandin formation, implicating that therapeutic application of low-dose NSAIDs could affect hemiketal levels while sparing prostaglandin formation and the associated gastrointestinal or cardiovascular side-effects. We will also prepare HKD2 and HKE2 by total chemical synthesis for comprehensive analysis of their biological effects. In Specific Aim 2 we will test the hypothesis that the hemiketals are formed through transcellular biosynthesis with a 5-LOX expressing leukocyte providing the 5-HETE substrate (e.g., a neutrophil, eosinophil, or basophil) for COX-2 expressed in an activated macrophage or endothelial cell. These studies will be complemented by the quantification of hemiketals in different stages of human atherosclerotic lesions as a prototypical inflammatory disease and in two animal models of spontaneous inflammation/resolution. In Specific Aim 3 we will determine the role and mechanism of hemiketals as regulators of endothelial cell tubulogenesis, monocyte adhesion to endothelial cells, and activation of receptors and transcription factors involved in the inflammatory response. Together these experiments are designed to define the 5-LOX/COX-2 derived hemiketals as novel lipid autacoids with a functional role in the regulation of the inflammatory process. Novel therapeutic applications of available anti- inflammatory medications are imminent.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel pathways in eicosanoid biosynthesis and metabolism
-
批准号:10672176
-
项目类别:
-
资助金额:$47.55万
-
财政年份:2022
-
负责人:Claus Schneider
-
依托单位:
Novel pathways in eicosanoid biosynthesis and metabolism
-
批准号:10330785
-
项目类别:
-
资助金额:$47.55万
-
财政年份:2022
-
负责人:Claus Schneider
-
依托单位:
Novel Pathways of Eicosanoid Metabolism
-
批准号:9445135
-
项目类别:
-
资助金额:$32.17万
-
财政年份:2017
-
负责人:Claus Schneider
-
依托单位:
Oxidative activation of the dietary cancer chemopreventive agent curcumin
-
批准号:8601172
-
项目类别:
-
资助金额:$43.18万
-
财政年份:2013
-
负责人:Claus Schneider
-
依托单位:
Oxidative activation of the dietary cancer chemopreventive agent curcumin
-
批准号:9207754
-
项目类别:
-
资助金额:$40.99万
-
财政年份:2013
-
负责人:Claus Schneider
-
依托单位:
Oxidative activation of the dietary cancer chemopreventive agent curcumin
-
批准号:8435168
-
项目类别:
-
资助金额:$44.87万
-
财政年份:2013
-
负责人:Claus Schneider
-
依托单位:
Pharmacokinetics and Metabolism of Oxidized Curcumin
-
批准号:8301157
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2012
-
负责人:Claus Schneider
-
依托单位:
Pharmacokinetics and Metabolism of Oxidized Curcumin
-
批准号:8540399
-
项目类别:
-
资助金额:$7.33万
-
财政年份:2012
-
负责人:Claus Schneider
-
依托单位:
Convergence of the COX-2 and 5-lipoxygenase pathways
-
批准号:7938289
-
项目类别:
-
资助金额:$5.51万
-
财政年份:2009
-
负责人:Claus Schneider
-
依托单位:
Convergence of the Cox-2 and 5-Lipoxygenase Pathways
-
批准号:8501525
-
项目类别:
-
资助金额:$30.26万
-
财政年份:2007
-
负责人:Claus Schneider
-
依托单位:
Convergence of the COX-2 and 5-lipoxygenase pathways
-
批准号:7541465
-
项目类别:
-
资助金额:$29.17万
-
财政年份:2007
-
负责人:Claus Schneider
-
依托单位:
Convergence of the Cox-2 and 5-Lipoxygenase Pathways
-
批准号:9762119
-
项目类别:
-
资助金额:$31.25万
-
财政年份:2007
-
负责人:Claus Schneider
-
依托单位:
Convergence of the Cox-2 and 5-Lipoxygenase Pathways
-
批准号:8370898
-
项目类别:
-
资助金额:$31.36万
-
财政年份:2007
-
负责人:Claus Schneider
-
依托单位:
Convergence of the Cox-2 and 5-Lipoxygenase Pathways
-
批准号:8688263
-
项目类别:
-
资助金额:$31.36万
-
财政年份:2007
-
负责人:Claus Schneider
-
依托单位:
Convergence of the Cox-2 and 5-Lipoxygenase Pathways
-
批准号:9918939
-
项目类别:
-
资助金额:$31.25万
-
财政年份:2007
-
负责人:Claus Schneider
-
依托单位:
Convergence of the COX-2 and 5-lipoxygenase pathways
-
批准号:7208628
-
项目类别:
-
资助金额:$27.09万
-
财政年份:2007
-
负责人:Claus Schneider
-
依托单位:
Convergence of the COX-2 and 5-lipoxygenase pathways
-
批准号:7335593
-
项目类别:
-
资助金额:$28.15万
-
财政年份:2007
-
负责人:Claus Schneider
-
依托单位:
Convergence of the COX-2 and 5-lipoxygenase pathways
-
批准号:7751846
-
项目类别:
-
资助金额:$28.87万
-
财政年份:2007
-
负责人:Claus Schneider
-
依托单位:
Convergence of the COX-2 and 5-lipoxygenase pathways
-
批准号:8071582
-
项目类别:
-
资助金额:$28.58万
-
财政年份:2007
-
负责人:Claus Schneider
-
依托单位:
海外基金